验证数据展示
经过测试的应用
| Positive IF/ICC detected in | Neuro-2a cells |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
CL488-82935 targets PAK7 in IF/ICC applications and shows reactivity with human samples.
| 经测试应用 | IF/ICC Application Description |
| 经测试反应性 | human |
| 免疫原 | PAK7 fusion protein Ag29190 种属同源性预测 |
| 宿主/亚型 | Rabbit / IgG |
| 抗体类别 | Recombinant |
| 产品类型 | Antibody |
| 全称 | p21 protein (Cdc42/Rac)-activated kinase 7 |
| 别名 | PAK4/6/7, PAK 5, p21-activated kinase 7, p21-activated kinase 5, KIAA1264 |
| 计算分子量 | 719 aa, 81 kDa |
| 观测分子量 | 70 kDa |
| GenBank蛋白编号 | BC024179 |
| 基因名称 | PAK7 |
| Gene ID (NCBI) | 57144 |
| 偶联类型 | CoraLite® Plus 488 Fluorescent Dye |
| 最大激发/发射波长 | 493 nm / 522 nm |
| 形式 | Liquid |
| 纯化方式 | Protein A purification |
| UNIPROT ID | Q9P286 |
| 储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
| 储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
PAK7, also known as PAK5, is a newly found but scarcely researched type II PAKs (PAK4, 5, 6). PAK7 was originally found in the brain, which promotes filopodia formation in nerve cells. Recently, studies have found that the expression level of PAK7 significantly increased in colorectal cancer, ovarian cancer, gastric cancer, neuroglioma, hepatocellular carcinoma, pancreatic cancer, osteosarcoma, and breast cancer. PAK7 plays an important role in tumorigenesis, invasion, and metastasis, mainly related to its mechanism of regulating cytoskeleton, inhibiting apoptosis, and promoting proliferation. The calculated molecular weight of PAK7 is 80 kDa (PMID: 29805709, PMID: 34165002).
实验方案
| Product Specific Protocols | |
|---|---|
| IF protocol for CL Plus 488 PAK7 antibody CL488-82935 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |